^
Association details:
| Biomarker: | BAG1 overexpression |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer
Published date:
09/29/2021
Excerpt:
Higher BAG1 under T-DM1 therapy had favorable impact on pCR, while higher CXXC5 or MAPT essentially reduced the relative efficacy of the T-DM1 therapy arms (vs. the trastuzumab arm).
DOI:
https://doi.org/10.3390/cancers13194884
Trial ID:
